CD44 and neoplasm: Enhanced arrest at G2-M phase of NAR-HA@CH-PCL-NP, when compared to NAR and enhanced survival rate of the animals in the treated group when compared with toxic group could both be due to enhanced localization and penetration of the drug into the leaky vasculature of tumor tissue and also the higher affinity of HA modified nanoparticles to overexpressed CD44.